+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Apidra"

From
From
From
Insulin Intelligence Center 2012-2023 - Product Thumbnail Image

Insulin Intelligence Center 2012-2023

  • Report
  • June 2024
  • Global
From
Diabetes Drug Intelligence Center 2012-2023 - Product Thumbnail Image

Diabetes Drug Intelligence Center 2012-2023

  • Report
  • June 2024
  • Global
From
From
From
From
From
From
From
From
From
From
From
From
US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026 - Product Thumbnail Image

US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026

  • Report
  • February 2021
  • 500 Pages
  • United States
From
Loading Indicator

Apidra is a brand of insulin glulisine, a fast-acting insulin analog used to treat diabetes mellitus. It is used to control high blood sugar in adults and children with type 1 diabetes and adults with type 2 diabetes. Apidra is a part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat endocrine and metabolic disorders such as diabetes, thyroid disorders, and obesity. These drugs are used to regulate hormones, metabolism, and other body functions. The Endocrine and Metabolic Disorders Drugs market is a rapidly growing market, driven by the increasing prevalence of diabetes and other endocrine and metabolic disorders. The market is expected to continue to grow in the coming years, driven by the increasing demand for new and improved treatments. Some of the major companies in the Apidra market include Sanofi, Eli Lilly, Novo Nordisk, Merck, and AstraZeneca. Show Less Read more